SCHEMBL243232

SCHEMBL243232

CCOC(=O)c1cnc(N2CCOCC2)nc1Nc1c(C)c(-c2ccccn2)nc2cc(F)cc(F)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.57
PIK3CA P42336 9/20 0.46
GAA P10253 6/20 0.42
MAPT P10636 6/20 0.42
ALOX15 P16050 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
TDP1 Q9NUW8 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
LMNA P02545 2/20 0.40
MC4R P32245 2/20 0.40
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTK2B Q14289 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPK1 P28482 2/20 0.40
CLK1 P49759 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
PIK3CB P42338 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL242110 0.91 PIK3CD (0.61) PIK3CDPIK3CAMAPK1PIK3CBPIK3CG
SCHEMBL3314799 0.82 PIK3CD (0.53) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL242377 0.80 PIK3CD (0.63) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL244881 0.80 PIK3CD (0.58) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL243055 0.80 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL241524 0.78 PIK3CD (0.54) PIK3CDPIK3CAALOX15LMNAMAPK1
SCHEMBL14849163 0.75 PIK3CD (0.68) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2712981 0.75 PIK3CD (0.79) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2711307 0.75 PIK3CD (0.70) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2712331 0.75 PIK3CD (0.63) PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588473-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
WO-2012003264-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003264-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PIK3CD 25/4885PIK3CA 26/4885GAA 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.